Recent applications of magnetic iron oxide nanoparticles for cerebral blood volume quantification in functional magnetic resonance imaging

Abstract

The use of iron oxide nanoparticles (IONPs) in magnetic resonance imaging (MRI) and the study of brain functions using MRI have been continuously evolving for more than 30 years. This contribution aims to explore the recent applications of magnetic IONPs in the study of the brain through functional MRI (fMRI), particularly focusing on their use in a specific parameter, that is, the cerebral blood volume (CBV), whose measurements are valued for their higher sensitivity and spatial specificity with respect to blood oxygen level-dependent (BOLD) fMRI analyses. This study will summarize the basis of the fMRI technique, explaining the types of experiments commonly conducted, the parameters involved, and discussing the main techniques that exploit magnetic nanoparticles and other materials as contrast agents, along with their potential applications in the imaging field. CBV measurements will be explained in general theoretical terms and compared with other methods. The key elements of magnetic nanoparticle production, including the most commonly used synthesis procedures and coating options, will be reported. Finally, the discussion will focus on how CBV-weighted (CBVw) images acquired using IONPs are currently being utilized in research.

Keywords

blood oxygenation level dependent / cerebral blood volume / contrast agents / functional magnetic resonance imaging / iron oxide nanoparticles

References

[1] Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci. 1992; 89(13):5951-5955.

[2] Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, Hyde JS. Time course EPI of human brain function during task activation. Magn Reson Med. 1992; 25(2):390-397.

[3] Yoo SS, Guttmann CRG, Panych LP. Multiresolution data acquisition and detection in functional MRI. Neuroimage. 2001; 14(6):1476-1485.

[4] Van Meer MP, Van Der Marel K, Otte WM, Berkelbach Van Der Sprenkel JW, Dijkhuizen RM. Correspondence between altered functional and structural connectivity in the contralesional sensorimotor cortex after unilateral stroke in rats: a combined resting-state functional MRI and manganese-enhanced MRI study. J Cereb Blood Flow Metab. 2010; 30(10):1707-1711.

[5] Huang Y, Ceceli AO, Kronberg G, et al. Association of cortico-striatal engagement during cue reactivity, reappraisal, and savoring of drug and non-drug stimuli with craving in heroin addiction. Am J Psychiatry. 2024; 181(2):153-165.

[6] Buxton RB. The physics of functional magnetic resonance imaging (fMRI). Rep Prog Phys. 2013; 76(9):096601.

[7] Di Corato R, Gazeau F, Le Visage C, et al. HigH-resolution Cellular MRI: gadolinium and iron oxide nanoparticles for in-depth dual-cell imaging of engineered tissue constructs. ACS Nano. 2013; 7(9):7500-7512.

[8] Gossuin Y, Martin E, Vuong QL, et al. Characterization of commercial iron oxide clusters with high transverse relaxivity. J Magn Reson Open. 2022; 10-11:100054.

[9] Westbrook C, Talbot J. MRI in Practice. Fifth edition. Wiley; 2019.

[10] Kim B, Kim H, Kim S, Hwang Y. A brief review of non-invasive brain imaging technologies and the near-infrared optical bioimaging. Appl Microsc. 2021; 51(1):9.

[11] Pelekanos V, Mok RM, Joly O, et al. Rapid event-related, BOLD fMRI, non-human primates (NHP): choose two out of three. Sci Rep. 2020; 10(1):7485.

[12] Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci. 1990; 87(24):9868-9872.

[13] Zhao F, Wang P, Hendrich K, Kim SG. Spatial specificity of cerebral blood volume-weighted fMRI responses at columnar resolution. Neuroimage. 2005; 27(2):416-424.

[14] Abreu R, Leal A, Figueiredo P. EEG-Informed fMRI: a review of data analysis methods. Front Hum Neurosci. 2018; 12:29.

[15] Biondetti E, Chiarelli AM, Germuska M, et al. Breath-hold BOLD fMRI without CO₂ sampling enables estimation of venous cerebral blood volume: potential use in normalization of stimulus-evoked BOLD fMRI data. Neuroimage. 2024; 285:120492.

[16] Zamboni E, Watson I, Stirnberg R, et al. Mapping curvature domains in human V4 using CBV-sensitive layer-fMRI At 3T. Front Neurosci. 2025; 19:1537026.

[17] Ogawa S, Menon RS, Kim SG, Ugurbil K. On the characteristics of functional magnetic resonance imaging of the brain. Annu Rev Biophys Biomol Struct. 1998; 27(1):447-474.

[18] Marrelec G, Bellec P, Benali H. Exploring large-scale brain networks in functional MRI. J Physiol Paris. 2006; 100(4):171-181.

[19] Dijkhuizen RM, Van Der Marel K, Otte WM, et al. Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke. Transl Stroke Res. 2012; 3(1):36-43.

[20] Alkolfat F, Abdel Galeel A, Bassiouny AR, Eldeeb H, Radwan A, Ashram YA. Patterns of visual task-based functional MRI activation in chronic posterior cerebral artery stroke patients. Clin Neuroradiol. 2023; 33(3):769-781.

[21] Frahm J, Dechent P, Baudewig J, Merboldt KD. Advances in functional MRI of the human brain. Prog Nucl Magn Reson Spectrosc. 2004; 44(1-2):1-32.

[22] Wang Y, Liu T. Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker. Magn Reson Med. 2015; 73(1):82-101.

[23] Matthews PM, Jezzard P. Functional magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2004; 75(1):6-12.

[24] Detre JA. Clinical applicability of functional MRI. J Magn Reson Imaging. 2006; 23(6):808-815.

[25] Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev. 2019; 99(1):949-1045.

[26] Chen JE, Glover GH. Functional magnetic resonance imaging methods. Neuropsychol Rev. 2015; 25(3):289-313.

[27] Buxton RB, Frank LR. A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation. J Cereb Blood Flow Metab. 1997; 17(1):64-72.

[28] Rogers BP, Morgan VL, Newton AT, Gore JC. Assessing functional connectivity in the human brain by fMRI. Magn Reson Imaging. 2007; 25(10):1347-1357.

[29] Wu K, Gollo LL. Mapping and modeling age-related changes in intrinsic neural timescales. Commun Biol. 2025; 8(1):167.

[30] Pan N, Qin K, Patino LR, et al. Aberrant brain network topology in youth with a familial risk for bipolar disorder: a task-based fMRI connectome study. J Child Psychol Psychiatry. 2024; 65(8):1072-1086.

[31] Ensel S, Uhrig L, Ozkirli A, et al. Transient brain activity dynamics discriminate levels of consciousness during anesthesia. Commun Biol. 2024; 7(1):716.

[32] Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci. 2003; 100(1):253-258.

[33] He J, Kurita K, Yoshida T, Matsumoto K, Shimizu E, Hirano Y. Comparisons of the amplitude of low-frequency fluctuation and functional connectivity in major depressive disorder and social anxiety disorder: a resting-state fMRI study. J Affect Disord. 2024; 362:425-436.

[34] Lenzi D, Raz E, Pantano P. FMRI and multiple sclerosis. Curr Med Imaging Rev. 2008; 4(3):163-169.

[35] Khazaee A, Ebrahimzadeh A, Babajani-Feremi A. Identifying patients with alzheimer's disease using resting-state fMRI and graph theory. Clin Neurophysiol. 2015; 126(11):2132-2141.

[36] Lunkova E, Guberman GI, Ptito A, Saluja RS. Noninvasive magnetic resonance imaging techniques in mild traumatic brain injury research and diagnosis. Hum Brain Mapp. 2021; 42(16):5477-5494.

[37] Mandino F, Cerri DH, Garin CM, et al. Animal functional magnetic resonance imaging: trends and path toward standardization. Front Neuroinform. 2020; 13:78.

[38] Jenkins BG. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. Neuroimage. 2012; 62(2):1072-1085.

[39] Khalili-Mahani N, Rombouts SARB, Van Osch MJP, et al. Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: a review of state-of-the-art, challenges, and opportunities for studying brain chemistry. Hum Brain Mapp. 2017; 38(4):2276-2325.

[40] Perera C, Harrison IF, Lythgoe MF, Thomas DL, Wells JA. Pharmacological MRI with simultaneous measurement of cerebral perfusion and blood-cerebrospinal fluid barrier function using interleaved echo-time arterial spin labelling. Neuroimage. 2021; 238:118270.

[41] Lin Z, Jiang D, Liu P, Ge Y, Moghekar A, Lu H. Blood–brain barrier permeability in response to caffeine challenge. Magn Reson Med. 2022; 88(5):2259-2266.

[42] Buxton RB. Introduction to Functional Magnetic Resonance Imaging: Principles and Techniques. 2nd ed. Cambridge University Press; 2009.

[43] Hua J, Liu P, Kim T, et al. MRI techniques to measure arterial and venous cerebral blood volume. Neuroimage. 2019; 187:17-31.

[44] Hennessee JP, Lung TC, Park DC, Kennedy KM. Age differences in BOLD modulation to task difficulty as a function of amyloid burden. Cerebral Cortex. 2024; 34(9):bhae357.

[45] Mandeville JB, Rosen BR. Functional MRI. In: Toga AW, Mazziotta JC, eds. Brain Mapping: The Methods. Elsevier; 2002:315-349.

[46] Kluytmans M, Van Der Grond J, Viergever MA. Gray matter and White matter perfusion imaging in patients with severe carotid artery lesions. Radiology. 1998; 209(3):675-682.

[47] Grubb RL, Raichle ME, Eichling JO, Ter-Pogossian MM. The effects of changes in PaCO₂ cerebral blood volume, blood flow, and vascular mean transit time. Stroke. 1974; 5(5):630-639.

[48] Stewart GN. Researches on the circulation time in organs and on the influences which affect it: parts I.—III. J Physiol. 1893; 15(1-2):1-89.

[49] Mandeville JB. IRON fMRI measurements of CBV and implications for BOLD signal. Neuroimage. 2012; 62(2):1000-1008.

[50] Kennerley AJ, Mayhew JE, Redgrave P, Berwick J. Vascular origins of BOLD and CBV fMRI signals: statistical mapping and histological sections compared. Open Neuroimag J. 2010; 4:1-8.

[51] Belliveau JW, Kennedy DN, McKinstry RC, et al. Functional mapping of the human visual cortex by magnetic resonance imaging. Science. 1991; 254(5032):716-719.

[52] Kim SG, Harel N, Jin T, Kim T, Lee P, Zhao F. Cerebral blood volume MRI with intravascular superparamagnetic iron oxide nanoparticles. NBM. 2013; 26(8):949-962.

[53] Alabousi M, Davenport MS. Use of intravenous gadolinium-based contrast media in patients with kidney disease and the risk of nephrogenic systemic fibrosis: Radiology in training. Radiology. 2021; 300(2):279-284.

[54] Slavu LM, Antonelli A, Scarpa ES, et al. Optimization of magnetic nanoparticles for engineering erythrocytes as theranostic agents. Biomater Sci. 2023; 11(9):3252-3268.

[55] Högemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem. 2000; 11(6):941-946.

[56] Thrippleton M, Blair G, Valdes-Hernandez M, et al. MRI relaxometry for quantitative analysis of USPIO uptake in cerebral small vessel disease. Int J Mol Sci. 2019; 20(3):776.

[57] Tong S, Zhu H, Bao G. Magnetic iron oxide nanoparticles for disease detection and therapy. Mater Today. 2019; 31:86-99.

[58] Di Corato R, Aloisi A, Rella S, et al. Maghemite nanoparticles with enhanced magnetic properties: one-pot preparation and ultrastable dextran shell. ACS Appl Mater Interfaces. 2018; 10(24):20271-20280.

[59] Das M, Oyarzabal EA, Chen L, et al. One-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applications. Neuroimage. 2021; 238:118213.

[60] Qiao R, Fu C, Forgham H, et al. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv Drug Deliv Rev. 2023; 197:114822.

[61] Wei H, Wiśniowska A, Fan J, et al. Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents. Proc Natl Acad Sci. 2021; 118(42):e2102340118.

[62] Lu AH, Salabas EL, Schüth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed. 2007; 46(8):1222-1244.

[63] Wu W, Wu Z, Yu T, Jiang C, Kim WS. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015; 16(2):023501.

[64] Noqta OA, Aziz AA, Usman IA, Bououdina M. Recent advances in iron oxide nanoparticles (IONPs): synthesis and surface modification for biomedical applications. J Supercond Novel Magn. 2019; 32(4):779-795.

[65] Figuerola A, Di Corato R, Manna L, Pellegrino T. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res. 2010; 62(2):126-143.

[66] Nisticò R, Cesano F, Garello F. Magnetic materials and systems: domain structure visualization and other characterization techniques for the application in the materials science and biomedicine. Inorganics. 2020; 8(1):6.

[67] Morales MP, Veintemillas-Verdaguer S, Montero MI, et al. Surface and internal spin canting in γ-Fe₂O₃ nanoparticles. Chem Mater. 1999; 11(11):3058-3064.

[68] Vasquez-Mansilla M, Zysler RD, Arciprete C, Dimitrijewits MI, Saragovi C, Greneche JM. Magnetic interaction evidence in α-Fe₂O₃ nanoparticles by magnetization and mössbauer measurements. J Magn Magn Mater. 1999; 204(1-2):29-35.

[69] Cardoso VF, Francesko A, Ribeiro C, Bañobre-López M, Martins P, Lanceros-Mendez S. Advances in magnetic nanoparticles for biomedical applications. Adv Healthcare Mater. 2018; 7(5):1700845.

[70] Arias LS, Pessan JP, Vieira APM, Lima TMT, Delbem ACB, Monteiro DR. Iron oxide nanoparticles for biomedical applications: a perspective on synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics. 2018; 7(2):46.

[71] Laurent S, Forge D, Port M, et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev. 2008; 108(6):2064-2110.

[72] Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater. 2010; 22(25):2729-2742.

[73] Muzzi B, Albino M, Gabbani A, et al. Star-shaped magnetic-plasmonic Au@Fe₃O₄ nano-heterostructures for photothermal therapy. ACS Appl Mater Interfaces. 2022; 14(25):29087-29098.

[74] Salem NFA, Abouelkheir SS, Yousif AM, et al. Large scale production of superparamagnetic iron oxide nanoparticles by the haloarchaeon Halobiforma sp. N1 and their potential in localized hyperthermia cancer therapy. Nanotechnology. 2021; 32(9):09LT01.

[75] Moya C, Batlle X, Labarta A. The effect of oleic acid on the synthesis of Fe_3−xO₄ nanoparticles over a wide size range. Phys Chem Chem Phys. 2015; 17(41):27373-27379.

[76] Liang Y, Jiang L, Xu S, et al. Synthesis and characterization of Fe₃O₄ nanoparticles prepared by solvothermal method. J Mater Eng Perform. 2024; 33(13):6804-6815.

[77] Masthoff IC, Kraken M, Mauch D, et al. Study of the growth process of magnetic nanoparticles obtained via the non-aqueous sol–gel method. J Mater Sci. 2014; 49(14):4705-4714.

[78] Dadfar SM, Roemhild K, Drude NI, et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325.

[79] Kritika RI. Therapeutic applications of magnetic nanoparticles: recent advances. Mater Adv. 2022; 20:74257444.

[80] Wang X, Li Y, Zhao J, et al. Magnetotactic bacteria: characteristics and environmental applications. Front Environ Sci Eng. 2020; 14(4):56.

[81] Parashar M, Shukla VK, Singh R. Metal oxides nanoparticles via sol–gel method: a review on synthesis, characterization and applications. J Mater Sci: Mater Electron. 2020; 31(5):3729-3749.

[82] Li X, Liu E, Zhang Z, Xu Z, Xu F. Solvothermal synthesis, characterization and magnetic properties of nearly superparamagnetic Zn-doped Fe₃O₄ nanoparticles. J Mater Sci: Mater Electron. 2019; 30(4):3177-3185.

[83] Gevart T, Freis B, Vangijzegem T, et al. Design of iron oxide nanoparticles as theranostic nanoplatforms for cancer treatment. In: Doudin B, Coey M, Cēbers A, eds. Magnetic Microhydrodynamics. 120. Topics in Applied Physics. Springer International Publishing; 2024:175-215.

[84] Salehipour M, Rezaei S, Mosafer J, Pakdin-Parizi Z, Motaharian A, Mogharabi-Manzari M. Recent advances in polymer-coated iron oxide nanoparticles as magnetic resonance imaging contrast agents. J Nanopart Res. 2021; 23(2):48.

[85] Dias AMGC, Hussain A, Marcos AS, Roque ACA. A biotechnological perspective on the application of iron oxide magnetic colloids modified with polysaccharides. Biotech Adv. 2011; 29(1):142-155.

[86] Yang J, Fan L, Xu Y, Xia J. Iron oxide nanoparticles with different polymer coatings for photothermal therapy. J Nanopart Res. 2017; 19(10):333.

[87] Zhang B, Tu Z, Zhao F, Wang J. Superparamagnetic iron oxide nanoparticles prepared by using an improved polyol method. Appl Surf Sci. 2013; 266:375-379.

[88] Easo SL, Mohanan PV. Dextran stabilized iron oxide nanoparticles: synthesis, characterization and in vitro studies. Carbohydr Polymers. 2013; 92(1):726-732.

[89] Hradil J, Pisarev A, Babič M, Horák D. Dextran-modified iron oxide nanoparticles. China Particuol. 2007; 5(1-2):162-168.

[90] Chen BW, Hatamie S, Garu P, et al. Synthesis of iron-oxide magnetic nanoparticles coated with dextran of varied molecular mass using a facile ball-milling method. Micro Nano Lett. 2020; 15(10):645-650.

[91] Liu C, Tan Y, Liu C, Chen X, Yu L. Preparations, characterizations and applications of chitosan-based nanoparticles. J Ocean Univer China. 2007; 6(3):237-243.

[92] Khmara I, Strbak O, Zavisova V, et al. Chitosan-stabilized iron oxide nanoparticles for magnetic resonance imaging. J Magn Magn Mater. 2019; 474:319-325.

[93] Soares PIP, Sousa AI, Ferreira IMM, Novo CMM, Borges JP. Towards the development of multifunctional chitosan-based iron oxide nanoparticles: optimization and modelling of doxorubicin release. Carbohydr Polymers. 2016; 153:212-221.

[94] Tønnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002; 28(6):621-630.

[95] Castelló J, Gallardo M, Busquets MA, Estelrich J. Chitosan (or alginate)-coated iron oxide nanoparticles: a comparative study. Colloids Surf A. 2015; 468:151-158.

[96] Etemadi H, Buchanan JK, Kandile NG, Plieger PG. Iron oxide nanoparticles: physicochemical characteristics and historical developments to commercialization for potential technological applications. ACS Biomater Sci Eng. 2021; 7(12):5432-5450.

[97] Lu CH, Hsiao JK. Diagnostic and therapeutic roles of iron oxide nanoparticles in biomedicine. Tzu Chi Med J. 2023; 35(1):11-17.

[98] Reimer P, Schuierer G, Balzer T, Peters PE. Application of a superparamagnetic iron oxide (Resovis^®) for MR imaging of human cerebral blood volume. Magn Reson Med. 1995; 34(5):694-697.

[99] Amemiya S, Akahane M, Aoki S, et al. Dynamic contrast-enhanced perfusion MR imaging with SPIO: a pilot study. Invest Radiol. 2009; 44(9):503-508.

[100] Wank I, Mittmann C, Kreitz S, et al. Neutral sphingomyelinase controls acute and chronic alcohol effects on brain activity. Neuropharmacology. 2024; 253:109948.

[101] Antonelli A, Pacifico S, Sfara C, Tamma M, Magnani M. Ferucarbotran-loaded red blood cells as long circulating MRI contrast agents: first in vivo results in mice. Nanomedicine. 2018; 13(7):675-687.

[102] Antonelli A, Magnani M. SPIO nanoparticles and magnetic erythrocytes as contrast agents for biomedical and diagnostic applications. J Magn Magn Mater. 2022; 541:168520.

[103] Béalle G, Di Corato R, Kolosnjaj-Tabi J, et al. Ultra magnetic liposomes for MR imaging, targeting, and hyperthermia. Langmuir. 2012; 28(32):11834-11842.

[104] Toth GB, Varallyay CG, Horvath A, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017; 92(1):47-66.

[105] Thill M, Kurylcio A, Welter R, et al. The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast. 2014; 23(2):175-179.

[106] Antonelli A, Sfara C, Magnani M. Intravascular contrast agents in diagnostic applications: use of red blood cells to improve the lifespan and efficacy of blood pool contrast agents. Nano Res. 2017; 10(3):731-766.

[107] Krischer B, Forte S, Niemann T, Kubik-Huch RA, Leo C. Feasibility of breast MRI after sentinel procedure for breast cancer with superparamagnetic tracers. Eur J Surg Oncol. 2018; 44(1):74-79.

[108] Qi HX, Reed JL, Wang F, et al. Longitudinal fMRI measures of cortical reactivation and hand use with and without training after sensory loss in primates. Neuroimage. 2021; 236:118026.

[109] Moon HS, Jiang H, Vo TT, Jung WB, Vazquez AL, Kim SG. Contribution of excitatory and inhibitory neuronal activity to BOLD fMRI. Cerebral Cortex. 2021; 31(9):4053-4067.

[110] Poplawsky AJ, Iordanova B, Vazquez AL, Kim SG, Fukuda M. Postsynaptic activity of inhibitory neurons evokes hemodynamic fMRI responses. Neuroimage. 2021; 225:117457.

[111] Zhao F, Wang X, Zariwala HA, et al. fMRI study of the role of glutamate NMDA receptor in the olfactory adaptation in rats: insights into cellular and molecular mechanisms of olfactory adaptation. Neuroimage. 2017; 149:348-360.

[112] Guthrie KM, Anderson AJ, Leon M, Gall C. Odor-induced increases in c-fos mRNA expression reveal an anatomical “unit” for odor processing in olfactory bulb. Proc Natl Acad Sci. 1993; 90(8):3329-3333.

[113] Schoppa NE, Kinzie JM, Sahara Y, Segerson TP, Westbrook GL. Dendrodendritic inhibition in the olfactory bulb is driven by NMDA receptors. J Neurosci. 1998; 18(17):6790-6802.

[114] Poplawsky AJ, Fukuda M, Kang B, Kim JH, Suh M, Kim SG. Dominance of layer-specific microvessel dilation in contrast-enhanced high-resolution fMRI: comparison between hemodynamic spread and vascular architecture with CLARITY. Neuroimage. 2019; 197:657-667.

[115] Cover C, Reddy S, Vazquez A, Fukuda M, Poplawsky AJ. Awake rodent fMRI: gradient-echo echo planar imaging versus compressed-sensing fast low-angle shot. Imaging Neurosci. 2025; 3:imag_a_00406.

[116] Poplawsky AJ, Cover C, Reddy S, Chishti HB, Vazquez A, Fukuda M. Odor-evoked layer-specific fMRI activities in the awake mouse olfactory bulb. Neuroimage. 2023; 274:120121.

[117] Han MJ, Park CU, Kang S, et al. Mapping functional gradients of the striatal circuit using simultaneous microelectric stimulation and ultrahigh-field fMRI in non-human primates. Neuroimage. 2021; 236:118077.

[118] Garcia-Garcia M, Nikolaidis A, Bellec P, et al. Detecting stable individual differences in the functional organization of the human basal ganglia. Neuroimage. 2018; 170:68-82.

[119] Vedaei F, Alizadeh M, Tantawi M, Romo V, Mohamed FB, Wu C. Vascular and neuronal effects of general anesthesia on the brain: an fMRI study. J Neuroimaging. 2023; 33(1):109-120.

[120] Le TT, Im GH, Lee CH, Choi SH, Kim SG. Mapping cerebral perfusion in mice under various anesthesia levels using highly sensitive BOLD MRI with transient hypoxia. Sci Adv. 2024; 10(9):eadm7605.

[121] Le TT, Choi SH, Im GH, et al. Whole-brain BOLD responses to graded hypoxic challenges at 7 T, 9.4 T, and 15.2 T: implications for ultrahigh-field functional and dynamic susceptibility contrast MRI. Magn Reson Med. 2025; 94(1):262-277.

[122] Ma Z, Duan Y, Fredriksson I, et al. Role of dorsal striatum circuits in relapse to opioid seeking after voluntary abstinence. Neuropsychopharmacology. 2025; 50:452-460.

[123] Bagdasarian FA, Larsen K, Deng HP, et al. Neurochemical characterization of 5-HT_2A R partial agonists with simultaneous PET-MRI. J Cereb Blood Flow Metab. 2024; 45(5):0271678X241302937.

[124] Cho S, Roy A, Liu CJ, et al. Cortical layer-specific differences in stimulus selectivity revealed with high-field fMRI and single-vessel resolution optical imaging of the primary visual cortex. Neuroimage. 2022; 251:118978.

[125] Shen H, Ma Z, Hans E, et al. Cocaine self-administration increases impulsive decision-making in low-impulsive rats associated with impaired functional connectivity in the mesocorticolimbic system. eNeuro. 2025; 12(3):ENEURO.0408-24.2025.

RIGHTS & PERMISSIONS

2025 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.